American Origin Unverified
This profile is unclaimed and has not been independently reviewed.
Claim & get verified
VO
Voyager Acquisition Corp./Cayman Islands
$17.11
-1.07%
NASDAQ: VACH · 15-min delayed
$335.2MMarket cap
$9.0MNet income
3Employees
VACHNASDAQ
2024IPO
About Voyager Acquisition Corp./Cayman Islands
Voyager Acquisition Corp is a blank check company.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Reported figures
Financial summary
- Net income
- $9.0M
- Total assets
- $270.1M
- Market cap
- $335.2M
Source: SEC EDGAR · updated Jun 8, 2026
Multi-year
Revenue & profit trend
FY2024
FY2025
Revenue Net income
FY 2025
Financial statements
Income statement
- Operating income
- -$1.8M
- Net income
- $9.0M
Balance sheet
- Total assets
- $270.1M
- Current assets
- $193.6K
- Total liabilities
- $13.3M
- Current liabilities
- $1.3M
- Shareholders’ equity
- -$13.1M
Cash flow
- Operating cash flow
- -$486.2K
- Net cash flow
- -$486.2K
Statements via Polygon.io (SEC filings)
NASDAQ: VACH
$17.11
-1.07%
15-minute delayed · data by Polygon.io
Past year
$9.53
$17.30
52-week range
- Market cap
- $335.2M
- Shares outstanding
- 19.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 30, 2024
Market data by Polygon.io · prices are 15-minute delayed
Auto-generated
At a glance
- Profitable — net income of $9.0M.
- Trading near its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Voyager Acquisition Corp./Cayman Islands.
Write a review
Newsroom
News about Voyager Acquisition Corp./Cayman Islands
VERAXA Biotech to Debut as a Publicly Traded Company Pioneering Next-Generation Cancer Therapies on June 11, 2026
VERAXA Biotech Strengthens Financial Position with $27.5 Million Principal Amount Senior Secured Note Financing and $50 Million Share Purchase Agreement
VERAXA Biotech and Secarna Pharmaceuticals Initiate Antibody Oligonucleotide Conjugate Alliance in Immunology
VERAXA Biotech to Attend Key Industry Conferences to Showcase BiTAC Technology Platform
VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program
News & sentiment via Polygon.io
Explore
Browse all →
